[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-malignant-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-malignant-tumors":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,65,93,122,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100443373","high-dose-rate-brachytherapy-for-the-treatment-of-both-primary-and-secondary-unresectable-liver-malignancies-100443373",false,"NCT05053555","High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies","Inclusion Criteria:\n\n* GROUP A: Patients with liver lesions must be over the age of 18\n* GROUP A: Any patient with up to five unresectable tumors that are:\n\n  * At least 3 cm (largest diameter in the axial plane)\n  * In close proximity to large blood vessels\n  * In close proximity to sensitive structures (bowel, stomach, diaphragm, liver capsule, liver hilum, bile ducts)\n  * Associated with difficult endovascular access to one or more feeding arterial branches (hypovascular tumors)\n  * Associated with a large shunt fraction to other vital organs\n* GROUP B: Historical patients who meet the above criteria for group A but did not receive HDRBT between 01\u002F01\u002F2000 and 1\u002F01\u002F2021\n\nExclusion criteria:\n\n* Active infectious disease\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Patients with polymetastatic disease with the exception of those patients who may benefit from therapy addressing local complications directly related to the target lesion diminishing quality of life such as pain, vascular\u002Fbiliary occlusion, and liver disfunction\n* Pregnancy (sexually active patients must be on birth control while participating in this study)\n* Child-Pugh class C\n* Total serum bilirubin \\> 2 mg\u002Fdl\n* Platelet count \\\u003C 50,000\u002Ful\n* International normalized ratio (INR) \\> 1.5","ALL","19 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies. These advances have resulted in a myriad of benefits for patients including decreased morbidity, mortality, as well as increased longevity and quality of life. However, these therapies can only be performed within certain parameters. Thermal ablative techniques such as radiofrequency ablation (RFA) and microwave ablation (MVA) are recommended for small lesions under 3 cm due to decreased efficacy when attempting to treat larger lesions. Additionally, large vessels in close proximity to a target lesion may result in heat dissipation, termed the \"heat sink\" effect, and result in incomplete ablation of the lesion. Furthermore, thermal ablative techniques cause off-target damage when utilized near sensitive structures such as the diaphragm, stomach, or bowel, and if performed near thermosensitive bile ducts, can result in cholestasis . Noting these limitations, percutaneous high-dose-rate brachytherapy was brought into clinical practice by Ricke et al. in Europe in 2002 . This therapy utilizes an iridium-192 (192Ir) isotope to administer a cytotoxic dose of radiation to a target lesion. It is not susceptible to heat sink effects and can also deliver radiation with the precision necessary to cause tumor death without destroying the integrity of neighboring structures. Additionally, it can be used to treat larger tumors (\\>3cm) as it is not associated the same size limitations as ablative techniques and can also be utilized to treat lesions that are not amenable to intra-arterial therapies (such as trans-arterial chemoembolization and yttrium-90 radioembolization).\n\nSince its inception, HDRBT has been evaluated through multiple studies investigating its use to treat lesions throughout the body including both primary and secondary liver malignancies such as hepatocellular carcinoma (HCC), cholangiocarcinoma, metastasis to the liver from colorectal cancer, pancreatic cancer , melanoma , and breast cancer . Its use in treating lymph node metastases has also been investigated . These studies have demonstrated the feasibility, safety, and clinical effectiveness of this method, establishing it as a therapeutic option when use of thermal ablation therapies is restricted. Most studies however, have been retrospective and have been performed outside the United States.\n\nStudying this therapy will add a crucial treatment option to our current armamentarium, filling a gap in currently available therapies and additionally allowing for further investigation of the use of HDRBT in a larger and more diverse population.",[25,26,27,28],"Liver Malignant Tumors","Cholangiocarcinoma Metastatic","Pancreatic Cancer","Melanoma","RECRUITING","2026-05-19",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2022-04-24",{"date":37,"type":19},"2027-01-31",{"name":39,"class":40},"M.D. Anderson Cancer Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100548899","clinical-effectiveness-of-microwave-ablation-using-starwave-microwave-generator-for-hepatic-malignancies-100548899","NCT06426992","Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies","Evaluation of Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Small Liver Malignancies: A Prospective Single Center Study","Inclusion Criteria:\n\n* Child-Pugh Class A or B\n* Patients with suspected hepatocellular carcinoma or residual\u002Frecurrent hepatocellular carcinoma of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days or Patients with suspected metastatic liver cancer of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days, for whom microwave thermal ablation is being considered\n\nExclusion Criteria:\n\n* In cases where there are three or more malignant liver tumors\n* When the maximum size of the tumor exceeds 4 cm\n* Diffuse infiltrative type of cancer with unclear tumor boundaries\n* When the tumor is adhered to the central hepatic portal vein, hepatic vein, or bile duct by 5 mm or more\n* Severe liver failure (Child-Pugh Class C)\n* In cases of vascular invasion by malignant liver tumors\n* Severe coagulopathy (platelet count below 50,000\u002Fmm³ or INR prolonged by more than 50%)\n* In cases of multiple extrahepatic metastases\n* Situations where it is highly unlikely to obtain appropriate data for research purposes","20 Years","85 Years",{"count":52,"type":19},128,[22],"The purpose of this study is to determine the technical success rate of creating a safety margin of 5 mm or more including the tumor by performing image-guided percutaneous microwave thermal therapy using a microwave generator and antenna developed by StarMed for the treatment of small liver cancer and the 1-year local recurrence rate based on follow-up imaging tests.",[25],"2026-04-08",{"date":58,"type":33},"2026-04-13",{"date":60,"type":33},"2024-04-30",{"date":62,"type":19},"2026-08-30",{"name":64,"class":40},"Seoul National University Hospital",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":15,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":20,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100625878","histotripsy-for-ablation-of-liver-tumours-in-asia-100625878","NCT07428356","Histotripsy for Ablation of Liver Tumours in Asia","Histotripsy Ablation for Liver Tumours (HALT): A Multi-centre Prospective Pilot Study on the Safety and Efficacy of Histotripsy in Asian Primary and Secondary Liver Malignancies","HALT","Inclusion Criteria:\n\n1. Age ≥21 years at the time of consent.\n2. Histologically\u002Fcytologically confirmed cancers (imaging diagnosis as per AASLD allowed for HCC):\n\n   A) Liver limited malignancies (primary or secondary) not eligible for\u002Fdeclined resection or other locoregional treatment modalities.\n\n   B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received \\> 3 months of systemic therapy).\n3. Characteristics of hepatic lesions intended for treatment:\n\n   * Up to 3 hepatic lesions.\n   * Tumour ≤ 3 cm in longest diameter.\n   * Lesion(s) must be visible and targetable by ultrasound.\n4. ECOG Performance Status 0-1.\n5. Child-Pugh class A or B7 liver function for patients with underlying cirrhosis.\n6. Adequate hematologic and organ function within 14 days prior to treatment:\n\n   * Haemoglobin ≥ 9.0 g\u002FdL\n   * Platelets ≥ 75,000\u002Fmm³\n   * INR ≤ 1.5 × ULN\n   * Estimated (by Cockroft-Gault or Modification of Diet in Renal Disease (MDRD) or measured creatinine clearance ≥ 50ml\u002Fmin.\n   * Total bilirubin ≤ 1.5 × upper limit normal or direct bilirubin ≤ ULN for participants with total bilirubin \\> 1.5 × ULN (participants with known history of elevated indirect bilirubin level suggestive of extrahepatic source of elevation e.g. Gilbert's disease may be recruited with bilirubin levels ≤ 3 × ULN)\n   * AST and ALT ≤ 5 × ULN\n7. Ability to undergo general anaesthesia, as confirmed by pre-anaesthetic assessment.\n8. Life expectancy ≥ 3 months in the opinion of the investigator.\n9. Willing and able to comply with study visits and procedures.\n10. Written informed consent obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n1. Extrahepatic disease progression requiring immediate systemic intervention, including new brain metastases or malignant ascites.\n2. Vascular invasion, defined as gross involvement or encasement of major portal vein or hepatic vein branches.\n3. Tumours located adjacent (\\\u003C5 mm) to hollow viscera (e.g., stomach, colon) where histotripsy poses perforation risk.\n4. Lesions poorly visualized on ultrasound or not targetable due to overlying ribs or gas.\n5. Severe or uncontrolled comorbidities including:\n\n   * Uncontrolled hypertension or cardiovascular disease\n   * Active infection (requiring systemic therapy)\n   * Severe chronic obstructive pulmonary disease or hypoxia\n6. Contraindications to general anaesthesia or surgery.\n7. Pregnancy or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment.\n8. Participation in another interventional trial within 4 weeks prior to enrollment, or concurrent participation in a therapeutic study.\n9. Any condition that, in the investigator's judgment, may compromise the patient's safety or interfere with protocol adherence.","21 Years","99 Years",{"count":76,"type":19},40,[22],"The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.",[25],[81,82],"Histotripsy","Ablation of Liver Tumours","2026-02-19",{"date":85,"type":33},"2026-02-23",{"date":87,"type":33},"2025-11-07",{"date":89,"type":19},"2029-05-07",{"name":91,"class":40},"National Cancer Centre, Singapore",3,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":15,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":20,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100611178","15-vs-45-minute-pringle-maneuver-in-liver-cancer-resection-randomized-noninferiority-trial-100611178","NCT07237204","15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial","A Prospective, Randomized Noninferiority Trial Comparing 15- and 45-minute Pringle Maneuvers During Liver Resection for Oncologic Indications.","Inclusion Criteria:\n\n* Diagnosis of a primary or secondary malignant liver tumor.\n* Age \\> 18 years.\n* Patient deemed eligible for liver resection.\n* WHO performance status ≤ 2.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Liver cirrhosis.\n* Liver dysfunction classified as Child-Pugh class B or C.\n* Repeat hepatectomy.\n* Prior ablation or chemoembolization of hepatic lesions.\n* Prior portal vein branch embolization.\n* Planned or performed ALPPS procedure.\n* Concomitant resection of any organ other than the gallbladder during the same operation.","18 Years",{"count":102,"type":19},600,[22],"The goal of this clinical trial is to evaluate the safety of two durations of the Pringle maneuver in adults undergoing elective liver resection for malignant tumors. The main questions it aims to answer are:\n\nIs the incidence of post-hepatectomy liver failure different between 15-minute and 45-minute Pringle maneuver durations?\n\n* Do the durations differ in operative time or intraoperative blood loss?\n* Researchers will compare patients randomized 1:1 to 15 minutes vs 45 minutes of Pringle clamping to see if outcomes are non-inferior between groups.\n\nParticipants will:\n\n* Undergo standard oncologic hepatectomy with the assigned Pringle duration.\n* Receive routine perioperative assessments, including laboratory tests and clinical evaluations.\n* Attend follow-up visits at approximately 6 months, 1 year, and 3 years after surgery.",[106,107,25],"Liver Cancer, Adult","Metastases to Liver",[109,110,111],"Pringle manouver","Liver malignancy","Liver resection","NOT_YET_RECRUITING","2025-11-14",{"date":115,"type":33},"2025-11-19",{"date":117,"type":19},"2025-12-01",{"date":119,"type":19},"2030-11-01",{"name":121,"class":40},"Medical University of Warsaw",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":15,"minAge":129,"maxAge":74,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":41},"100359417","molecular-basis-of-pediatric-liver-cancer-100359417","NCT03959800","Molecular Basis of Pediatric Liver Cancer","Genetic and Molecular Basis of Pediatric Liver Cancer","Inclusion Criteria:\n\n* Prior or current treatment for a childhood liver tumor, malignant or benign, at age \\\u003C21 years.\n* Biological parents and siblings of eligible children.\n\nExclusion Criteria:\n\n* No prior or current treatment for a childhood liver tumor.\n* Non-biological parents, legal guardians, or non-biological siblings of eligible children.","0 Years",{"count":131,"type":19},1600,"OBSERVATIONAL","The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.",[135,25,136,137,138,139],"Childhood Liver Cancer","Embryonal Sarcoma of Liver (Disorder)","Hepatoblastoma","Hepatocellular Carcinoma","Rhabdoid Tumor of Liver",[137,138,141],"Pediatric Liver Cancer","2025-09-05",{"date":144,"type":33},"2025-09-12",{"date":146,"type":33},"2015-06-22",{"date":148,"type":19},"2029-06-30",{"name":150,"class":40},"University of Pittsburgh",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":15,"minAge":100,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":20,"phases":161,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":41},"100553559","tace-combined-with-immune-checkpoint-inhibitors-for-liver-malignant-tumors-100553559","NCT06487663","TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors","Transcatheter Hepatic Artery Chemoembolization Combined With Immune Checkpoint Inhibitors for Liver Tumors","TIKET","Inclusion Criteria:\n\n* Confirmed diagnosis of HCC by histology\u002F cytology or clinical criteria\n* Sign informed consent\n* When screening for age, the age should be ≥ 18 years old\n* Eligible for TACE treatment\n* ECOG physical condition score is 0 or 1\n* No prior systemic therapy for HCC, especially immunotherapy\n* According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation\n\nExclusion Criteria:\n\n* Have any history of kidney disease or nephrotic syndrome\n* Evidence of extrahepatic spread (EHS)\n* Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control\n* Any condition representing a contraindication to TACE as determined by the investigators\n* Known genetic factors for bleeding or thrombosis; Any previous or current evidence indicating a tendency for bleeding\n* Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4 treatment)\n* Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepatic artery chemoembolization), TAE (hepatic artery embolization), or TARE (hepatic artery radiation embolization)\n* Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis.","75 Years",{"count":76,"type":19},[22],"This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.",[164,165,166,25],"Hepatocellular Carcinoma Non-resectable","Cholangiocarcinoma Non-resectable","Liver Metastases",[138,168,166,25],"Cholangiocarcinoma","2024-06-27",{"date":171,"type":33},"2024-07-05",{"date":173,"type":33},"2020-10-27",{"date":175,"type":19},"2026-10-27",{"name":177,"class":40},"Tianjin Medical University Cancer Institute and Hospital"]